O12. Survival of patients with advanced EGFR-mutated NSCLC treated with EGFR TKIS in routine clinical practice

BACKGROUND: The use of epidermal growth factor receptor (EGFR) TKIs in EGFR-mutated non-small cell lung cancer (NSCLC) moved the survival boundary for these patients up to impressive 19 to 35 months, as reported in seven randomized clinical trials (RCTs). In addition, latest results of RCTs show sig...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Transl Lung Cancer Res
Main Authors: Hitij, Nina Turnsek, Sadikov, Aleksander, Knez, Lea, Mohorcic, Katja, Jakelj, Andraz, Cufer, Tanja
Formato: Artigo
Idioma:Inglês
Publicado em: Pioneer Bioscience Publishing Company 2014
Assuntos:
CELCC 2014 Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4367788/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2218-6751.2014.AB011
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados